These findings provide important support for the efficacy of anti-angiogenic agents — the clinical potential of which has been questioned. The drug is currently being tested in Phase III trials ...

Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Epithelial Ovarian Cancer.

Work is being done on tumor specific agents that attack only cancer cells. Anti-angiogenic drugs - Anti-angiogenic drugs contain organic or synthetic molecules that can block the formation of new ...

Risks include the non-standard comparator in the pivotal trial and the historically low success rate of novel anti-angiogenic therapies in solid tumors. Despite risks, CMPX's market cap suggests a ...

INR:5098. drawing of kho kho Stem cell therapy becomes the recommended treatment for severe COVID-19 patients, praised by the Ministry of Science and Technolog ...